CrystecPharma is pleased to announce that we have secured a six-figure loan from NPIF II – Mercia Debt Finance to support the next phase of our growth.
The funding follows a period of strong commercial momentum and will enable us to scale our operations, increase capacity, create new jobs and continue advancing our innovative mSAS® particle engineering technology.
CEO Paul Thorning added “This investment marks an important milestone for CrystecPharma as we continue to build on our recent growth and expand our capabilities. Demand for innovative formulation and drug delivery solutions continues to increase across the pharmaceutical industry, and this funding will help us strengthen our operations, support our growing client base and advance the development of technologies that have the potential to improve healthcare outcomes worldwide.”
Read more about the funding below
Funding boost for pharmatech firm replacing injections with inhalers – Mercia